STAT3 and ovarian carcinoma: Furthermore, a recent publication demonstrates that Olaparib-treated macrophages functionally suppress T cell-driven antitumor immune responses (38), and STAT3 activation has been reported to be essential for immune-suppressive macrophage differentiation in advanced epithelial ovarian cancer (39).